西安高新区的无尘车间里，陕西光电子先导院科技有限公司总经理杨军红指着刚刚通线的西北地区首条 8英寸硅光中试线说："这条线一贯通，我们将缩短光电、硅光客户的流片周期约30%，加速客户技术迭 代与产品升级。" 在全球光子产业竞争版图中，中试环节长期是制约创新的瓶颈。杨军红指出，全球硅光中试资源大多集 中在欧美企业手中，国内企业依托国外平台流片需支付高昂费用，且面临流片周期长、产能优先供给受 限等问题。 日前，陕西"追光计划"迎来标志性突破——西北地区首条8英寸硅光中试线在陕西光电子先导院正式通 线。这个投资7.5亿元的平台，不仅填补了区域硅光芯片中试领域空白，更成为陕西打造千亿级光子产 业集群的核心支点。 作为陕西光子产业的关键推手，光电子先导院正在探索一条从实验室到市场的独特路径。 破解中试困境 创新"平台+基金"模式 运营中试平台面临天然的商业挑战——设备利用率低，单纯依靠流片服务难以实现盈亏平衡。对此，光 电子先导院探索出了独特的"平台+基金"模式。 "我们是产业基金的LP，基金本身对项目有赋能作用，平台对项目也有技术以及产业加速的赋能作用。 项目发展快，我们有股权投资的收益，这部分股权投资的收益能弥补平台 ...

西安高新区的无尘车间里，陕西光电子先导院科技有限公司总经理杨军红指着刚刚通线的西北地区首条 8英寸硅光中试线说："这条线一贯通，我们将缩短光电、硅光客户的流片周期约30%，加速客户技术迭 代与产品升级。" 日前，陕西"追光计划"迎来标志性突破——西北地区首条8英寸硅光中试线在陕西光电子先导院正式通 线。这个投资7.5亿元的平台，不仅填补了区域硅光芯片中试领域空白，更成为陕西打造千亿级光子产 业集群的核心支点。 作为陕西光子产业的关键推手，光电子先导院正在探索一条从实验室到市场的独特路径。 破解中试困境 在全球光子产业竞争版图中，中试环节长期是制约创新的瓶颈。杨军红指出，全球硅光中试资源大多集 中在欧美企业手中，国内企业依托国外平台流片需支付高昂费用，且面临流片周期长、产能优先供给受 限等问题。 "中试平台区别于量产代工线。"杨军红解释，芯片设计公司从产品研发到大批量生产前，需要产品迭代 的过程，而传统代工厂的标准化工艺难以快速反馈这种高度定制化需求。 陕西光电子先导院的定位正是填补这一市场缝隙。杨军红表示，平台有意愿帮助创新主体进行从研发到 中试的小批量订单服务，而这正是大型量产工厂通常不愿承接的。 "我们不 ...

● 本报记者何昱璞 陕西光电子先导院的定位正是填补这一市场缝隙。杨军红表示，平台有意愿帮助创新主体进行从研发到 中试的小批量订单服务，而这正是大型量产工厂通常不愿承接的。 "我们不是要做抄答案的人，我们要做给答案的人。"杨军红表示，光电子先导院不追求简单的模式复 制，而是致力于解决行业真实痛点。 这一战略已初见成效。8英寸硅光平台刚刚通线，就与10余家头部企业达成意向合作协议，并吸引了多 家外地企业聚集陕西。深圳瑞识智能科技有限公司董事长汪洋评价："在陕西进行中试，排队时间短、 效率高，速度比在国外快数倍。" 创新"平台+基金"模式 西安高新区的无尘车间里，陕西光电子先导院科技有限公司总经理杨军红指着刚刚通线的西北地区首条 8英寸硅光中试线说："这条线一贯通，我们将缩短光电、硅光客户的流片周期约30%，加速客户技术迭 代与产品升级。" 日前，陕西"追光计划"迎来标志性突破——西北地区首条8英寸硅光中试线在陕西光电子先导院正式通 线。这个投资7.5亿元的平台，不仅填补了区域硅光芯片中试领域空白，更成为陕西打造千亿级光子产 业集群的核心支点。 作为陕西光子产业的关键推手，光电子先导院正在探索一条从实验室到市场的独 ...

● 本报记者 何昱璞 西安高新区的无尘车间里，陕西光电子先导院科技有限公司总经理杨军红指着刚刚通线的西北地区首条 8英寸硅光中试线说："这条线一贯通，我们将缩短光电、硅光客户的流片周期约30%，加速客户技术迭 代与产品升级。" 这一战略已初见成效。8英寸硅光平台刚刚通线，就与10余家头部企业达成意向合作协议，并吸引了多 家外地企业聚集陕西。深圳瑞识智能科技有限公司董事长汪洋评价："在陕西进行中试，排队时间短、 效率高，速度比在国外快数倍。" 创新"平台+基金"模式 日前，陕西"追光计划"迎来标志性突破——西北地区首条8英寸硅光中试线在陕西光电子先导院正式通 线。这个投资7.5亿元的平台，不仅填补了区域硅光芯片中试领域空白，更成为陕西打造千亿级光子产 业集群的核心支点。 作为陕西光子产业的关键推手，光电子先导院正在探索一条从实验室到市场的独特路径。 破解中试困境 在全球光子产业竞争版图中，中试环节长期是制约创新的瓶颈。杨军红指出，全球硅光中试资源大多集 中在欧美企业手中，国内企业依托国外平台流片需支付高昂费用，且面临流片周期长、产能优先供给受 限等问题。 "中试平台区别于量产代工线。"杨军红解释，芯片设计公司从 ...

必创科技（300667.SZ）12月15日在投资者互动平台表示，在量子科学实验方面，公司的相关产品主要 应用于搭建量子科学实验的仪器和测量系统，包括：用于光路搭建的光学调整架、精密位移台、光学隔 振平台等产品，用于信号探测的光谱仪与探测器相关产品，以及用于NV色心测量的ODMR与反聚束测 量系统。上述产品及应用产生的订单规模较小，敬请投资者注意投资风险。 每经AI快讯，有投资者在投资者互动平台提问：公司产品在量子科技领域的布局进展如何？ （记者 胡玲） ...

Investment Rating - The report maintains a "Recommended" rating for the company, with a current price of 111.68 yuan [5]. Core Views - The company achieved a cumulative operating revenue of 1.55 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 14.2%. The net profit attributable to the parent company was 470 million yuan, up 20.6% year-on-year [1]. - In Q3 2025, the company reported an operating revenue of 480 million yuan, a significant year-on-year increase of 46.2%, and a net profit of 140 million yuan, up 64.4% year-on-year [1]. - The increase in net profit is attributed to the growth in solution services, core component business, and detector business compared to the same period last year [1][2]. Summary by Sections Financial Performance - The gross profit margin for Q3 2025 was 49.8%, a decrease of 3.8 percentage points year-on-year, while the net profit margin increased by 64.4% to 1.4% [1]. - The company’s expense ratio decreased by 2.7 percentage points year-on-year, with sales, management, R&D, and financial expense ratios at 5.1%, 4.8%, 15.3%, and 0.2%, respectively [1]. Market Trends - The medical device bidding market in China showed robust growth, with overall market sizes in the first three quarters of 2025 increasing by 67.5%, 61.7%, and 29.8% year-on-year, respectively [2]. - The public bidding market for medical imaging equipment grew by 55.02% year-on-year in Q3 2025, indicating strong demand [2]. Business Development - The company has made significant progress in the development of various medical tube products, including micro-focus tubes and dental tubes, with several products entering the commercialization phase [2]. - The solution business is expected to continue driving growth, benefiting from the recovery in downstream demand, with projected revenues of 2.16 billion, 2.61 billion, and 3.20 billion yuan for 2025, 2026, and 2027, respectively [3][4].

Investment Rating - The report maintains an "Accumulate" rating for the company, indicating a positive outlook for the stock over the next 6 to 12 months [3][8]. Core Views - The company reported strong performance in Q3 2025, with revenue reaching 1.549 billion yuan, a year-on-year increase of 14.22%, and a net profit attributable to shareholders of 471 million yuan, up 20.61% year-on-year. In Q3 alone, revenue was 482 million yuan, reflecting a significant growth of 46.18% year-on-year, and net profit increased by 64.43% [4][5]. - The growth in revenue is attributed to several factors, including the domestic medical equipment replacement policy, stable partnerships with leading dental equipment manufacturers, and increased demand in industrial testing from lithium battery manufacturers [6][7]. - The company has maintained a high level of R&D investment, with R&D expenses amounting to 228 million yuan in the first three quarters of 2025, accounting for 14.71% of revenue [7][8]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 1.549 billion yuan, with a net profit of 471 million yuan. The Q3 results showed a revenue of 482 million yuan and a net profit of 136 million yuan [4][5]. - The sales gross margin was 51.98%, a decrease of 2.30 percentage points year-on-year, while the net profit margin improved to 29.48%, an increase of 1.57 percentage points [6]. Growth Drivers - The company benefited from the domestic medical device replacement policy, which boosted demand in the medical imaging sector. Additionally, it became a major supplier in the Korean dental CBCT market, contributing to the recovery of its dental business [6][7]. - New core components and solutions saw significant growth, with some areas exceeding 50% year-on-year growth [6]. R&D and Innovation - The company continues to invest heavily in R&D, with a focus on new technologies and products. In the first half of 2025, it filed 28 new intellectual property applications, including 14 invention patents [7][8]. - As of June 2025, the company had a total of 594 registered or authorized intellectual properties, including 198 invention patents [7]. Future Outlook - The report projects that the company's net profit attributable to shareholders will reach 642 million yuan in 2025, 793 million yuan in 2026, and 963 million yuan in 2027, with corresponding P/E ratios of 38.7, 31.4, and 25.8 [8][10].

Core Insights - The company reported strong financial performance for the first three quarters of 2025, with revenue of 1.549 billion yuan, a year-on-year increase of 14.22%, and a net profit attributable to shareholders of 471 million yuan, up 20.61% [1] - In Q3 2025, the company achieved revenue of 482 million yuan, a significant year-on-year growth of 46.18%, and a net profit of 136 million yuan, which is a 64.43% increase compared to the same period last year [1][2] Growth Analysis - The revenue growth in Q3 2025 is attributed to several factors: the domestic medical equipment replacement policy boosting demand, stable partnerships with leading dental equipment manufacturers, recovery in industrial inspection demand from lithium battery manufacturers, and significant growth in new core components and solutions [2] - The net profit growth in Q3 is supported by scale advantages and effective cost control, with a notable increase in profitability expected as industry conditions improve [2] Profitability Analysis - For the first three quarters of 2025, the company's gross profit margin was 51.98%, a decrease of 2.30 percentage points year-on-year, primarily due to changes in product mix [2] - The net profit margin increased to 29.48%, up 1.57 percentage points year-on-year, driven by reductions in sales, management, and financial expense ratios [2] Operational Efficiency and Cash Flow - The company improved its inventory turnover days to 296.96 days, a decrease of 59.05 days year-on-year, indicating better inventory management [3] - Accounts receivable turnover days also improved to 125.41 days, down 13.22 days year-on-year, reflecting enhanced operational efficiency [3] - Operating cash flow showed a significant recovery, with a net cash flow from operating activities of 1.099 billion yuan, a year-on-year increase of 453.59% [3] R&D Investment - The company maintained high levels of R&D investment, with R&D expenses of 228 million yuan for the first three quarters, accounting for 14.71% of revenue [3] - The company made substantial progress in intellectual property, with 28 new applications for various types of IP in the first half of 2025, including 14 invention patent applications [3] Stock Incentive Plans - In October 2025, the company completed its stock incentive plans, granting 1.863 million shares of restricted stock and 410,000 stock appreciation rights to 199 individuals, including key executives [4] - The incentive plans are designed to support the company's long-term growth, with performance targets set for net profit growth in 2026 and 2027 [4] Future Outlook - The company is expected to maintain rapid revenue growth due to recovering demand in the industry and ongoing product and technology advancements [2][4] - Forecasted net profits for 2025, 2026, and 2027 are 642 million yuan, 793 million yuan, and 963 million yuan, respectively, with corresponding price-to-earnings ratios indicating a positive outlook [4]

Core Insights - The company reported a significant increase in revenue and net profit for the third quarter of 2025, with revenue reaching 482 million yuan, a year-on-year growth of 46.18%, and net profit of 136 million yuan, up 64.43% [1] - For the first three quarters of 2025, the company achieved a total revenue of 1.549 billion yuan, reflecting a year-on-year increase of 14.22%, and a net profit of 471 million yuan, which is a 20.61% increase compared to the previous year [1] - The growth in third-quarter performance is attributed to substantial increases in system solutions, core components, and detector businesses compared to the same period last year [1]

Core Viewpoint - The article emphasizes the importance of domestic innovation and collaboration in the high-end scientific instrument industry, highlighting the need for breakthroughs in core technologies and the integration of the industrial chain to promote the development of domestic high-end scientific instruments [2][9][23]. Summary by Sections Event Overview - The "2025 High-end Scientific Instrument Localization Technology and Industry Collaborative Innovation Salon" was held in Beijing, focusing on core technology breakthroughs, industrial collaboration, and policy recommendations in the high-end scientific instrument sector [2]. Keynote Report - The keynote speaker, Suo Jishuan, pointed out that scientific instruments are crucial for building a strong technological nation, but China heavily relies on imports for high-end instruments, which restricts technological innovation. He noted that despite government support since the "12th Five-Year Plan," there remains a gap between investment and actual industry needs [9][10]. - He introduced three development models: the "Zeiss model" focusing on key technologies, the "Thermo Fisher model" emphasizing platform development through mergers and acquisitions, and the "Danaher model" concentrating on forming leading enterprises [9][10]. Special Report - Han Li discussed the bottlenecks in the development of core components for high-end scientific instruments, stating that support for core component research is significantly lower than for complete systems, with only about 15% of funding allocated to core components [12][13]. - He highlighted the reliance on imports for many critical components and the need for a collaborative innovation platform involving government, research institutions, and enterprises to address these challenges [14]. Roundtable Discussion - The roundtable participants identified three main challenges in collaborative innovation: reliance on foreign technology for core components, a fragmented industrial ecosystem, and a lack of high-level talent in the field [16][17]. - They proposed solutions including policy guidance, collaboration between academia and industry, and leveraging AI technology to enhance efficiency and reduce dependency on manual operations [18][19]. Industry Expectations - The participants noted that current international trade restrictions present an opportunity for domestic scientific instrument development, urging the industry to focus on technological innovation and the leadership role of major enterprises [19][20]. - They called for sustained policy support for high-end instruments and emphasized the importance of building a robust talent pool and academic framework to achieve long-term industry growth [20][24]. Event Conclusion - Li Xin, Vice Chairman of the Beijing Association for Science and Technology, summarized the challenges and opportunities in the localization of high-end scientific instruments, noting that 70.9% of high-end instruments priced over 500,000 yuan are imported [23][24]. - She stressed the need for a systematic approach to innovation and collaboration across sectors to strengthen the foundation for technological self-reliance [24].